Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer.

Tytuł:
Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer.
Autorzy:
Santa-Inez DC; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Fuziwara CS; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Saito KC; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Kimura ET; Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Jul 27; Vol. 22 (15). Date of Electronic Publication: 2021 Jul 27.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
CRISPR-Cas Systems*
Gene Editing*
Gene Targeting*
MicroRNAs*/biosynthesis
MicroRNAs*/genetics
RNA, Neoplasm*/biosynthesis
RNA, Neoplasm*/genetics
Thyroid Carcinoma, Anaplastic*/genetics
Thyroid Carcinoma, Anaplastic*/metabolism
Thyroid Carcinoma, Anaplastic*/pathology
Thyroid Neoplasms*/genetics
Thyroid Neoplasms*/metabolism
Thyroid Neoplasms*/pathology
Animals ; Cell Line ; Cell Movement/genetics ; Cell Survival/genetics ; Heterografts ; Humans ; Mice ; Neoplasm Transplantation
References:
Bioinformatics. 2003 Jul 22;19(11):1439-40. (PMID: 12874059)
J Clin Endocrinol Metab. 2013 Feb;98(2):E196-205. (PMID: 23264400)
Thyroid. 2018 Jul;28(7):945-951. (PMID: 29742974)
Nat Rev Cancer. 2013 Mar;13(3):184-99. (PMID: 23429735)
Int J Mol Sci. 2020 Jan 19;21(2):. (PMID: 31963842)
Mol Ther. 2017 Feb 1;25(2):368-378. (PMID: 28153089)
Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891)
Cell. 2015 Aug 13;162(4):885-99. (PMID: 26255770)
Science. 2012 Aug 17;337(6096):816-21. (PMID: 22745249)
Endocr Relat Cancer. 2006 Jun;13(2):497-508. (PMID: 16728577)
Thyroid. 2018 Dec;28(12):1627-1641. (PMID: 30244634)
Nucleic Acids Res. 2019 Jul 2;47(W1):W171-W174. (PMID: 31106371)
Cell. 2013 Sep 12;154(6):1380-9. (PMID: 23992846)
Onco Targets Ther. 2020 Feb 13;13:1311-1319. (PMID: 32103998)
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80. (PMID: 16365291)
J Clin Endocrinol Metab. 2013 Aug;98(8):E1401-9. (PMID: 23783103)
Cell. 2014 Oct 23;159(3):676-90. (PMID: 25417114)
Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991)
Oncol Rep. 2017 Nov;38(5):2735-2740. (PMID: 29048684)
PLoS One. 2016 Mar 24;11(3):e0151968. (PMID: 27011326)
Oncogene. 2012 Apr 12;31(15):1910-22. (PMID: 21874046)
Cancer. 2013 Dec 15;119(24):4358-65. (PMID: 24301304)
Nat Biotechnol. 2013 Sep;31(9):827-32. (PMID: 23873081)
Thyroid. 2010 May;20(5):489-94. (PMID: 20406109)
Oncogene. 2018 Jun;37(25):3369-3383. (PMID: 29353884)
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61. (PMID: 16461460)
J Clin Endocrinol Metab. 2008 May;93(5):1600-8. (PMID: 18270258)
Nat Cell Biol. 2019 Dec;21(12):1468-1478. (PMID: 31792376)
Cancer Res. 2003 Apr 1;63(7):1454-7. (PMID: 12670889)
Annu Rev Biophys. 2017 May 22;46:505-529. (PMID: 28375731)
Biochem Biophys Res Commun. 2015 Jul 10;462(4):314-21. (PMID: 25960292)
Cancer Res. 2015 Oct 1;75(19):4119-30. (PMID: 26282166)
Cell. 2015 Jun 4;161(6):1374-87. (PMID: 26027739)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
Nat Commun. 2018 May 15;9(1):1911. (PMID: 29765029)
Thyroid. 2020 Jan;30(1):81-94. (PMID: 31578932)
Nature. 2005 Jun 9;435(7043):834-8. (PMID: 15944708)
Oncogene. 2019 Jul;38(27):5486-5499. (PMID: 30967628)
Sci Rep. 2016 Apr 15;6:24356. (PMID: 27079678)
Cell. 2016 Jan 14;164(1-2):81-90. (PMID: 26748718)
BMC Cancer. 2016 Feb 16;16:108. (PMID: 26883911)
Oncogene. 2007 Nov 29;26(54):7590-5. (PMID: 17563749)
Ann Surg Oncol. 2011 Jul;18(7):2035-41. (PMID: 21537871)
Thyroid. 2021 Mar;31(3):337-386. (PMID: 33728999)
Nat Protoc. 2013 Nov;8(11):2281-2308. (PMID: 24157548)
Oncogene. 2019 Aug;38(34):6172-6183. (PMID: 31285550)
Grant Information:
430756/2018-6 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 430756/2018-6 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 2019/25116-8 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2019/17282-5 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2019/19865-8 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2020/10403-9 Fundação de Amparo à Pesquisa do Estado de São Paulo; Code 001 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; PNPD 88887.374682/2019-00 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; NapmiR Universidade de São Paulo
Contributed Indexing:
Keywords: CRISPR/Cas9n; anaplastic thyroid cancer; gene editing; miR-146b; microRNA
Substance Nomenclature:
0 (MIRN146 microRNA, human)
0 (MicroRNAs)
0 (RNA, Neoplasm)
Entry Date(s):
Date Created: 20210807 Date Completed: 20210909 Latest Revision: 20210909
Update Code:
20240105
PubMed Central ID:
PMC8348963
DOI:
10.3390/ijms22157992
PMID:
34360757
Czasopismo naukowe
Thyroid cancer is the most common endocrine malignancy, and the characterization of the genetic alterations in coding-genes that drive thyroid cancer are well consolidated in MAPK signaling. In the context of non-coding RNAs, microRNAs (miRNAs) are small non-coding RNAs that, when deregulated, cooperate to promote tumorigenesis by targeting mRNAs, many of which are proto-oncogenes and tumor suppressors. In thyroid cancer, miR-146b-5p is the most overexpressed miRNA associated with tumor aggressiveness and progression, while the antisense blocking of miR-146b-5p results in anti-tumoral effect. Therefore, inactivating miR-146b has been considered as a promising strategy in thyroid cancer therapy. Here, we applied the CRISPR/Cas9n editing system to target the MIR146B gene in an aggressive anaplastic thyroid cancer (ATC) cell line. For that, we designed two single-guide RNAs cloned into plasmids to direct Cas9 nickase (Cas9n) to the genomic region of the pre-mir-146b structure to target miR-146b - 5p and miR-146b - 3p sequences. In this plasmidial strategy, we cotransfected pSp-Cas9n- miR-146b -GuideA-puromycin and pSp-Cas9n- miR-146b -GuideB-GFP plasmids in KTC2 cells and selected the puromycin resistant + GFP positive clones (KTC2-Cl). As a result, we observed that the ATC cell line KTC2-Cl1 showed a 60% decrease in the expression of miR-146b-5p compared to the control, also showing reduced cell viability, migration, colony formation, and blockage of tumor development in immunocompromised mice. The analysis of the MIR146B edited sequence shows a 5 nt deletion in the miR-146b-5p region and a 1 nt deletion in the miR-146b-3p region in KTC2-Cl1. Thus, we developed an effective CRISPR/Cas9n system to edit the MIR146B miRNA gene and reduce miR-146b-5p expression which constitutes a potential molecular tool for the investigation of miRNAs function in thyroid cancer.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies